NCT01554020撤回2 期
Effect of Blood Sugar Take Care on Glucose Metabolism, Determinants of Metabolic Syndrome, and Quality of Life in Prediabetic Adults: A Randomized, Double-blind, Placebo-controlled Study
NewChapter, Inc.2 个研究点 分布在 1 个国家开始时间: 2012年6月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 试验地点
- 2
- 主要终点
- Fasting glucose
研究概览
简要总结
This prospective international clinical trial is a two-arm, double-blind, randomized, placebo-controlled, parallel-group, multicenter study. 112 prediabetic subjects will be randomized to Blood Sugar Take Care or placebo. Randomization will be stratified by gender. The intervention period is 12 weeks. The primary outcome is fasting glucose levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •SUBJECT INCLUSION CRITERIA: STEP 1
- •Age ≥ 18 years
- •Subject meets American Diabetes Association criteria for diabetes testing in asymptomatic, undiagnosed individuals:
- •If age ≥45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia
- •If age <45 years, subject must have a body mass index ≥ 25 kg/m2 for United States and ≥ 24 kg/m2 for Indonesia AND present with at least one of the following risk factors:
- •Have a first-degree relative with diabetes
- •Habitually physically inactive
- •Race is African-American, Hispanic American, Native American, Asian American, or Pacific Islander
- •Have delivered a baby weighing >9 lb or have been diagnosed with gestational diabetes mellitus
- •Hypertensive (≥140/90)
- •Known HDL cholesterol level 35 mg/dl
- •Known triglyceride level ≥250 mg/dl
- •On previous testing, had impaired glucose tolerance or impaired fasting glucose
- •History of vascular disease
- •Stable body weight (<5% change) in the last 3 months
- •Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (females only)
- •Able to understand the nature and purpose of the study including potential risks and side effects
- •Willing to consent to study participation and to comply with study requirements
排除标准
- •Known diabetes (type I or II)
- •Recent use (within 2 weeks of screening) of any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose or lipid metabolism
- •Recent use (within 4 weeks of screening) of any prescription or OTC medication that significantly affects glucose or lipid metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, systemic corticosteroids, statins, fibrates, niacin, and bile acid sequestrants
- •Daily use of nonsteroidal anti-inflammatory drugs (NSAIDS); (daily baby aspirin use acceptable)
- •Any comorbidity that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
- •Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
- •Eating disorder
- •Polycystic ovary syndrome
- •Known allergies to any substance in the study product
- •Pregnant or breastfeeding women
- •History of alcohol, drug, or medication abuse
- •Participation in another study with any investigational product within 3 months of screening
- •Recent (<3 months) gastrointestinal surgery or any planned surgery during the treatment period
- •SUBJECT INCLUSION CRITERIA: STEP 2
- •Fasting glucose between 95 and 130 mg/dl, based on portable glucometer reading
- •SUBJECT INCLUSION CRITERIA: STEP 3
- •Impaired fasting glucose, based on the American Diabetes Association definition of fasting serum glucose between 100 and 125 mg/dl
- •Impaired glucose tolerance, based on the American Diabetes Association definition of serum glucose between 140 and 199 mg/dl 2 hours after a 75 g glucose load
结局指标
主要结局
Fasting glucose
时间窗: 12 weeks
次要结局
- Insulin sensitivity index(12 weeks)
- Fasting insulin(12 weeks)
- Homeostasis Model Assessment of Insulin Resistance(12 weeks)
- Quantitative insulin sensitivity check index(12 weeks)
- Insulin secretion/insulin resistance index(12 weeks)
- Glycosylated hemoglobin (HbA1c)(12 weeks)
- High-sensitivity C-reactive protein(12 weeks)
- High-molecular weight adiponectin(12 weeks)
- Lipids (total cholesterol, HDL, LDL, VLDL, triglycerides)(12 weeks)
- Body composition(12 weeks)
- WHO Quality of Life Questionnaire(12 weeks)
- Comprehensive metabolic panel(12 weeks)
- Complete blood count(12 weeks)
- Adverse events(12 weeks)
- Gastrointestinal Symptom Rating Scale(12 weeks)
- Pulse(12 weeks)
- Blood pressure(12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)DiabetesNCT01240980Bristol-Myers Squibb104
已完成
3 期
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes MellitusDiabetesDiabetes Mellitus, Type 2NCT02773368Novo Nordisk A/S420
尚未招募
3 期
Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM PatientsDiabetes Mellitus Type 2 Without ComplicationNCT05688332University of Zambia118
已完成
3 期
Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)Type 2 Diabetes MellitusNCT00032487VA Office of Research and Development1,791
已完成
不适用
A Trial to Study the Effect of Vitamin D Supplementation on Glucose and Insulin Metabolism in Centrally Obese MenDiabetes Mellitus, Non-Insulin-DependentObesityNCT00347542Sitaram Bhartia Institute of Science and Research100